Kallikrein 9 antibody (C-Term) (HRP)
Quick Overview for Kallikrein 9 antibody (C-Term) (HRP) (ABIN8003944)
Target
See all Kallikrein 9 (KLK9) AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- C-Term
-
Purpose
- Anti-Kallikrein 9/KLK9 Antibody HRP Conjugated
-
Specificity
- No cross reactivity with other proteins.
-
Cross-Reactivity (Details)
- No cross-reactivity with other proteins
-
Purification
- Immunogen affinity purified.
-
Immunogen
- A synthetic peptide corresponding to a sequence at the C-terminus of human Kallikrein 9.
-
Isotype
- IgG
-
-
-
-
Application Notes
- Western blot, Optimal dilutions should be determined by end users. Immunohistochemistry (Paraffin-embedded Section), Optimal dilutions should be determined by end users. ELISA, Optimal dilutions should be determined by end users.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Buffer
- Each vial contains 50 % glycerol, 0.9 % NaCl, 0.2 % Na2HPO4.
-
Storage
- -20 °C
-
Storage Comment
- At -20°C for one year from date of receipt. Avoid repeated freezing and thawing.
-
Expiry Date
- 12 months
-
-
- Kallikrein 9 (KLK9)
-
Alternative Name
- KLK9
-
Background
-
Background: KLK9 (kallikrein-related peptidase 9) also known as kallikrein 9 or KLK-L3, belongs to the kallikrein subgroup of serine proteases, which have diverse physiologic functions in many tissues. The KLK9 gene contains 5 coding exons and is mapped to 19q13.41. The KLK9 gene is regulated by steroid hormones in a human breast cancer cell line. Yousef et al. (2001) performed a quantitative analysis of KLK9 expression in ovarian cancer. The results indicated thatKLK9 is under steroid hormone regulation in ovarian and breast cancer cell lines. KLK9 is a potential independent favorable prognostic marker for early-stage, low-grade, optimally debulked ovarian cancer patients.
Gene Full Name: kallikrein related peptidase 9
Sequence Similarities: Belongs to the peptidase S1 family. Kallikrein subfamily.
-
Gene ID
- 284366
-
UniProt
- Q9UKQ9
-
Pathways
- Complement System
Target
-